Navigation Links
'American Drug War II: Cannabis Destiny' is IMDB's Highest Rated 2013 Documentary
Date:7/9/2013

COLORADO SPRINGS, Colo., July 8, 2013 /PRNewswire/ -- The X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company specializing primarily in cannabinoid formulation-based health and wellness solutions, is proud to announce that "American Drug War II:  Cannabis Destiny" rated as the highest of all 2013 documentaries with a score of 9.7 out of 10.

The film focuses on the failed U.S. drug war and its affect on a new generation of children.  As IMDB states, "Director Kevin Booth navigates through the cutting edge of Cannabis research while becoming a foster parent to a child court ordered to take powerful mind altering drugs."

http://www.imdb.com/search/title?sort=user_rating&title_type=documentary&year=2013,2013

CFO and SR VP of Business Development of X-Change Corp, Robert Kane, stated, "It has been one of the greatest professional experiences of my life to work with Kevin Booth and his team.  It is a privilege to be part of the project from the inception of the business plan, through production and release.  To have it #1 on this year's IMDB highest rated documentary list is telling of the quality of production and the power of the film's message.  This is important because the story speaks to our country's failed drug policy within a context of inhumane effects on children in need of treatment.   We are thankful that the documentary includes the poignant story of little Cash Hyde.   The interest in this film is a game changing moment for both the film and entertainment industry as well as the Cannabis industry as the film's success establishes that the market is primed for further investment from media and entertainment giants to support, fund, and invest in related projects."

The film is available on DirecTV Video on Demand.  It is also available on iTunes:  https://itunes.apple.com/us/movie/american-drug-war-2-cannabis/id635644281?ls=1.  In addition, it is available as a Video on Demand from Amazon:  http://www.amazon.com/American-Drug-War-Cannabis-Destiny/dp/B00CO0LPWG/ref=sr_1_20?s=instant-video&ie=UTF8&qid=1370536759&sr=1-20.  

About The X-Change Corporation

The X-Change Corporation is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the hemp plant. Medicinal properties of hemp have been known and applied for thousands of years.  With the aid of scientific research The X-Change Corporation is translating such knowledge into development of effective cosmeceutical, nutraceutical, and food brands throughout the world. The Company's cosmetics and nutritional lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.
President
Dr. Dorothy Bray
info@xchangecorp.com 
www.xchangecorp.com 
1.866.326.5595

Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
rkane@xchangecorp.com
561.420.4824


'/>"/>
SOURCE X-Change Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Academy of Family Physicians Foundation Launches Cities for Life
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
7. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
11. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):